Sorrento Collaborates with Mount Sinai to Develop Ab Combination for Neutralizing SARS-CoV-2 and other Emerging Variants of COVID-19
Shots:
- The companies signed an exclusive license agreement to develop COVISHIELD + two mAb cocktail against emerging variants of SARS-CoV-2 including UK (B.1.1.7)- South Africa (B.1.351)- and Japan/Brazil (B.1.128) variants
- The pre-clinical development of Ab combination (IV and intranasal) including Sorrento and Mount Sinai Abs is underway
- The collaboration follows Sorrento’s efforts to eradicate COVID-19 which includes STI-2020 (COVI-AMG) and STI-2099 (COVIDROPS). The license contemplates Sorrento and Mount Sinai pursuing future collaborations in developing humanized mAb for therapeutic applications
Ref: GlobeNewswire | Image: PRNewswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com